From the President and Board Chair
We are pleased to present PATH’s 2010 annual report. We hope you’ll find this year’s review informative and enjoyable.
PATH is making significant strides in helping people around the world have a chance at a healthy life. One of our most visible milestones in 2010 was introduction of the MenAfriVac™ vaccine, which PATH and the World Health Organization developed together through our partnership in the Meningitis Vaccine Project. In December, 20 million people in Burkina Faso, Mali, and Niger were vaccinated against meningitis A, which has ravaged sub-Saharan Africa in epidemic waves for more than a century. In the process, the world witnessed how new global health models—pioneering partnerships, country-driven priorities, and an unrelenting focus on impact—are saving lives in some of the world’s poorest areas.
PATH has proven that simple and affordable technologies can be among the most effective. This is evident in the MenAfriVac story and in many of the projects described on the following pages. Innovation is at the core of what we do and how we do it.
We are most grateful for your continued engagement in our work and our vision of a world where innovation ensures that health is within reach for everyone. Thank you for your commitment to global health.
Christopher J. Elias, MD, MPH
President and CEO
Molly Joel Coye, MD, MPH
Chair, Board of Directors